| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
Nodes: 1975,
Authors: 5409,
Journals: 512,
Outer References: 13295,
Words: 3300
Collection span: 1980 - 2004
View: Overview. Sorted by date.
Page 6: 1 2 3 4 5 6 7
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1501 | 0 | 0 | 1349 2002 NOV 16 BLOOD 100(11):375A-375A Alvi S; Borok RZ; Shaher A; Anthwal S; Shaikh M; Alvi I; Tahir S; John P; Shetty V; Galili N; Raza A Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients. | 0 | 0 |
| 1502 | 0 | 0 | 1350 2002 NOV 16 BLOOD 100(11):377B-377B Lincz LF; Enno A Thalidomide induced alterations in multiple myeloma cell surface receptor expression do not affect adhesion to bone marrow stroma or correlate with VEGF secretion in vitro. | 0 | 0 |
| 1503 | 0 | 0 | 1351 2002 NOV 16 BLOOD 100(11):380B-380B Waage A; Romstad L; Brenne AT; Gimsing P; Juliusson G; Turesson I; Borset M; Sundan A Low serum levels of soluble tumor necrosis factor receptors predict for response to thalidomide in advanced myeloma. | 0 | 1 |
| 1504 | 0 | 0 | 1352 2002 NOV 16 BLOOD 100(11):384B-384B Devabhaktuni YD; Laber DA Secondary plasma cell leukemia associated with thalidomide in a patient with multiple myeloma. | 0 | 0 |
| 1505 | 0 | 0 | 1353 2002 NOV 16 BLOOD 100(11):384B-384B Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Anagnostopoulos N; Gika D; Margaritis D; Economopoulos T Clarithromycin, thalidomide and dexamethasone for the treatment of Waldenstrom's macroglobulinemia. | 0 | 0 |
| 1506 | 0 | 0 | 1354 2002 NOV 16 BLOOD 100(11):384B-384B Fawaz A; Magro L; Leleu X; Depil S; Guillerm G; Corm S; Bauters F; Facon T; Yakoub-Agha I Impact of thalidomide on survival of patients with multiple myeloma. | 0 | 2 |
| 1507 | 0 | 0 | 1355 2002 NOV 16 BLOOD 100(11):385B-385B Caravita T; Arciprete F; Siniscalchi A; Santinelli S; Iani C; Amadori S Thalidomide induced neuropathy in patients treated for multiple myeloma. | 0 | 0 |
| 1508 | 0 | 0 | 1356 2002 NOV 16 BLOOD 100(11):387B-387B Helgason HH; Smit WM; de Groot MR; Schenkeveld CEI; Neef C; Schaafsma MR Long term survival and complete remission of chemotherapy refractory multiple myeloma with thalidomide. | 0 | 0 |
| 1509 | 0 | 0 | 1357 2002 NOV 16 BLOOD 100(11):387B-387B Dmoszynska A; Manko J; Jawniak D; Ciepluch H; Hellmann A; Wolska-Smolen T; Skotnicki A; Soroka-Wojtaszko M; Urbanska-Rys H; Konopka L; Hus M Toxicity of thalidomide in multiple myeloma patients (long-term observations). | 0 | 0 |
| 1510 | 0 | 0 | 1358 2002 NOV 16 BLOOD 100(11):387B-387B Meng HT; Jin J; Mai WY Thalidomide plus M2 chemotherapy in the treatment of refractory multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1511 | 0 | 0 | 1359 2002 NOV 16 BLOOD 100(11):388B-388B Musto P; Falcone A; Sanpaolo G; La Sala A; Mantuano S; Cascavilla N; Melillo L; Dell'Olio M; Nobile M; Bodenizza C; Carella AM A combined therapy with thalidomide, dexamethasone and zoledronate is highly effective and well tolerated in pre-treated patients with multiple myeloma. | 0 | 1 |
| 1512 | 0 | 0 | 1360 2002 NOV 16 BLOOD 100(11):389B-389B Keyzner A; Kumar A; Besa EC The role of thalidomide and pamidronate in maintenance of plateau phase after second and third induction therapy in relapsed multiple myeloma patients. | 0 | 0 |
| 1513 | 0 | 0 | 1361 2002 NOV 16 BLOOD 100(11):389B-389B Huang JW; Wang YH; Du HP; Zhang J Thalidomide combined with conventional melphalan and predisone regimen for treatment of mulitiple myeloma | 0 | 0 |
| 1514 | 0 | 0 | 1362 2002 NOV 16 BLOOD 100(11):390B-390B Breitkreutz I; Cremer FW; Benner A; Raab MS; Moehler T; Egerer G; Christensen O; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection (PBSC) after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide (Thai) administration. | 0 | 0 |
| 1515 | 0 | 0 | 1363 2002 NOV 16 BLOOD 100(11):390B-390B Sato N; Kakimoto T; Hattori Y; Okamoto S; Morita K; Tanigawara Y; Ikeda Y Thalidomide induced severe neutropenia during the treatment of multiple myeloma via direct suppression of bone marrow hematopoiesis. | 0 | 0 |
| 1516 | 0 | 0 | 1364 2002 NOV 16 BLOOD 100(11):390B-390B Sidra GM; Russell N; Byrne J; Myers B; Mitchell D Combination therapy with thalidomide, cyclophosphamide and dexamethasone (C-ThaD) for VAD-refractory and relapsed myeloma. | 0 | 0 |
| 1517 | 0 | 0 | 1365 2002 NOV 16 BLOOD 100(11):390B-390B Alegre A; Gil-Fernandez JJ; Font P; Alonso A; Sureda A; Martinez-Chamorro C; Escudero A; Sanchez-Godoy P; Burgaleta C; Casado LF; Granda A; Aguado B; Osorio S; Nistal S; Mascunano R; Prieto E; Fernandez-Ranada JM Thalidomide as rescue of relapses after haematopoietic transplantation in multiple myeloma and as maintenance treatment: Results of a Spanish multicentre study including 63 patients. | 0 | 0 |
| 1518 | 0 | 0 | 1366 2002 NOV 16 BLOOD 100(11):392B-392B Kazmi MA; Cuadrado MJ; Karim MY; Jones RJ; Khamashta MA; Schey SA Comparison of thalidomide toxicity profiles in treatment of Lupus and myeloma: Efficacy and toxicity are not dose dependent. | 0 | 0 |
| 1519 | 0 | 0 | 1367 2002 NOV 16 BLOOD 100(11):393B-393B Moehler TM; Schlenzka J; Kasper B; Neben K; Egerer G; Ho AD; Goldschmidt H Low incidence of deep venous thrombosis in poor prognosis multiple myeloma patients treated with thalidomide and CED chemotherapy. | 0 | 0 |
| 1520 | 0 | 0 | 1368 2002 NOV 16 BLOOD 100(11):393A-393A Bahlis NJ; Sawney R; Gerson S PKC delta inhibition induces cell death in thalidomide and dexamethasone resistant multiple myeloma cell lines. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1521 | 0 | 0 | 1369 2002 NOV 16 BLOOD 100(11):394A-395A Minnema MM; Fijnheer R; De Groot PG; Lokhorst HM Factor VIII procoagulant activity as risk factor for deep venous thrombosis in patients with Multiple Myeloma during treatment with thalidomide. | 0 | 0 |
| 1522 | 0 | 0 | 1370 2002 NOV 16 BLOOD 100(11):397A-397A Palladini G; Perfetti V; Obici L; Merlini G Thalidomide toxicity in patients with AL (primary) amyloidosis. | 0 | 4 |
| 1523 | 0 | 0 | 1371 2002 NOV 16 BLOOD 100(11):398A-398A Zangari M; Barlogie B; Anaissie FJ; Saghafifar F; Fassas A; Lee CK; Thertulien R; van Rhee F; Zeldis J; Fink L; Tricot G Abrogation of thrombogenic effect of the doxorubicin (DOX)- thalidomide (THAL) combination as part of total therapy II (TTII) for newley diagnosed multiple myeloma (MM) by effective anti-coagulation with low molecular weight heparin (LMWH). | 0 | 2 |
| 1524 | 0 | 0 | 1372 2002 NOV 16 BLOOD 100(11):398A-398A Dispenzieri A; Lacy MQ; Rajkumar SV; Geyer SM; Fonseca R; Witzig TE; Lust JA; Greipp PR; Kyle RA; Gertz MA High doses of thalidomide are not well tolerated in patients with primary systemic amyloidosis. | 0 | 2 |
| 1525 | 0 | 0 | 1373 2002 NOV 16 BLOOD 100(11):401A-402A Prince M; Mileshkin L; Biagi JJ; Smith JG; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Simmons PJ; Zeldis JB A multicentre phase-II trial of thalidomide in relapsed/refractory multiple myeloma (MM) reveals a dominant adverse prognostic impact of advanced age. | 0 | 0 |
| 1526 | 0 | 0 | 1374 2002 NOV 16 BLOOD 100(11):402A-402A Oakervee HE; McBride NC; Hemmaway CJ; Brownell A; Cervi P; Crawley C; Gale R; Grant I; Hamblin M; Lewis D; Rahemtulla A; Barnett MJ; Cavenagh JD Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. | 0 | 2 |
| 1527 | 0 | 0 | 1375 2002 NOV 16 BLOOD 100(11):402A-403A Kropff MH; Lang N; Bisping G; Domine N; Schneider P; Suedhoff T; Innig G; Straka C; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in advanced multiple myeloma: Final results of a phase II trial. | 0 | 1 |
| 1528 | 0 | 0 | 1376 2002 NOV 16 BLOOD 100(11):403A-403A Hussein MA; Elson P; Tsoe EA; Karam M; Srkaloci G Doxil (D), vincristine (V), decadron (D) and thalidomide (T) (DVd-T) for relapsed/refractory multiple myeloma (RMM). | 0 | 5 |
| 1529 | 0 | 0 | 1377 2002 NOV 16 BLOOD 100(11):403A-404A Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer S; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma. | 0 | 0 |
| 1530 | 0 | 0 | 1378 2002 NOV 16 BLOOD 100(11):426B-426B Santos E; Goodman M; Byrnes JJ; Fernandez HF Thalidomide as maintenance therapy in the post-transplantation setting in patients with multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1531 | 0 | 0 | 1379 2002 NOV 16 BLOOD 100(11):434A-434A Ghobrial IM; Kumar S; Porrata LF; Gertz MA; Gastineau DA; Ansell SM; Lacy MQ; Rajkumar VS; Micallef IN; Tefferi A; Dispenzieri A; Inwards D; Litzow MR; Markovic SN Thalidomide does not affect immune reconstitution post-autologous bone marrow transplantation in Multiple Myeloma. | 0 | 0 |
| 1532 | 0 | 0 | 1380 2002 NOV 16 BLOOD 100(11):477B-477B Cottler-Fox M; Barlogie B; Anaissie E; Zangari M; Fassas A; Lee CK; van Rhee F; Thertulien R; Tricot G Determinants of high and low CD 34 yield after CAD as part of Total Therapy II (TT II) for newly diagnosed Multiple Myeloma (MM): Effect of Thalidomide (THAL). | 0 | 0 |
| 1533 | 0 | 0 | 1381 2002 NOV 16 BLOOD 100(11):671A-671A LeBlanc R; Hideshima T; Hayashi T; Catley LP; Burger R; Shringarpure R; Cheema P; Richardson P; Anderson KC; Munshi NC Thalidomide analogue IMiD3 provides T cell co-stimulation through B7-CD28 pathway. | 0 | 0 |
| 1534 | 0 | 0 | 1382 2002 NOV 16 BLOOD 100(11):795A-795A Raza A; Lisak LA; Tahir S; Billmeier JM; Willmann HS; Alvi MI; Patkar S; Khan T; Rizvi A; Venugopal P; Gezer S; Mundle SD; Reddy PL Trilineage responses to arsenic trioxide (Trisenox (R)) and thalidomide in patients with myelodysplastic syndromes (MDS), particularly those with inv(3)(q21q26.2). | 0 | 0 |
| 1535 | 0 | 0 | 1383 2002 NOV 16 BLOOD 100(11):800A-800A Barosi G; Elliott M; Canepa L; Ballerini F; Piccaluga PP; Visani G; Marchetti M; Pozzato G; Zorat F; Tefferi A Thalidomide in Myelofibrosis with Myeloid Metaplasia: A pooled-analysis of individual patient data from five studies. | 0 | 0 |
| 1536 | 0 | 0 | 1384 2002 NOV 16 BLOOD 100(11):808A-809A Weber D; Albitar M; Delasalle K; Dey A; Rankin K; Gavino M; Walker P; Alexanian R Correlation of peripheral blood plasma levels of angiogenesis factors with treatment of thalidomide (T) or thalidomide-dexamethasone (TD) in prevoiusly untreated patients with multiple myeloma (MM). | 0 | 1 |
| 1537 | 0 | 0 | 1385 2002 NOV 16 BLOOD 100(11):811A-811A Thompson MA; Witzig TE; Timm MM; Haug J; Kumar S; Fonseca R; Greipp PR; Rajkumar SV Angiogenesis and angiogenic cytokines in patients receiving thalidomide for multiple myeloma (MM). | 0 | 1 |
| 1538 | 0 | 0 | 1386 2002 NOV 16 BLOOD 100(11):813A-813A Richardson P; Jagannath S; Schlossman R; Alsina M; Desikan RK; Blood E; Weller E; Mitsiades C; Hideshima T; Davies F; Doss D; Freeman A; Bosch J; Patin J; Dalton W; Anderson KC Thalidomide for relapsed multiple myeloma after high dose therapy and stem cell transplantation: Results of an open-label, multicenter phase two study of efficacy, toxicity and correlation with biological activity. | 0 | 0 |
| 1539 | 0 | 0 | 1387 2002 NOV 16 BLOOD 100(11):815A-815A Hayashi T; Hideshima T; Akiyama M; Munshi N; Chauhan D; Anderson KC Mechanisms whereby immunomedulatory analogs of thalidomide augment autologous NK cell anti-myeloma immunity. | 0 | 1 |
| 1540 | 0 | 0 | 1388 2002 NOV 16 BLOOD 100(11):816A-816A Treston AM; Swartz GM; Conner B; Shah J; Pribluda VS Pre-clinical evaluation of a thalidomide analog with activity against multiple myeloma and solid tumors - ENMD-0995 (S-(-)3- (3-amino-phthalimido)-glutarimide). | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1541 | 11 | 20 | 1524 2002 20021121-03:05:49 [NOV 21] LEUKEMIA & LYMPHOMA 43(12):2301-2307 Giovanni B; Michelle E; Letizia C; Filippo B; Paolo PP; Giuseppe V; Monia M; Gabriele P; Francesca Z; Ayalew T Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies | 0 | 0 |
| 1542 | 7 | 11 | 1281 2002 NOV 22 AIDS 16(17):2355-2356 Teo S; Noormohamed F; Youle M; Johnson M; Peters B; Stirling D; Thomas S Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing | 1 | 1 |
| 1543 | 5 | 5 | 1410 2002 NOV 23 BRITISH MEDICAL JOURNAL 325(7374):1245-1245 Ashby J; Tinwell H Thalidomide is not a human mutagen | 0 | 0 |
| 1544 | 19 | 51 | 1416 2002 20021129-15:19:17 [NOV 29] CANCER INVESTIGATION 20(7-8):1051-1058 Jaslow R; Kaplan G; Lyons L; Michaeli J; Coleman M Thalidomide in multiple myeloma-from the clinic to the laboratory | 0 | 0 |
| 1545 | 24 | 39 | 1389 2002 DEC 1 BLOOD 100(12):4162-4168 Yaccoby S; Johnson CL; Mahaffey SC; Wezeman MJ; Barlogie B; Epstein J Antimyeloma efficacy of thalidomide in the SCID-hu model | 1 | 6 |
| 1546 | 8 | 26 | 1284 2002 DEC [15] ALIMENTARY PHARMACOLOGY & THERAPEUTICS 16(12):2115-2122 Ginsburg PM; Ehrenpreis ED A pilot study of thalidomide for patients with symptomatic mesenteric panniculitis | 0 | 1 |
| 1547 | 30 | 59 | 1390 2002 DEC [15] BLOOD REVIEWS 16(4):207-215 Strasser K; Ludwig H Thalidomide treatment in multiple myeloma | 3 | 4 |
| 1548 | 6 | 7 | 1406 2002 DEC [15] BRITISH JOURNAL OF HAEMATOLOGY 119(3):883-884 Gonzalez-Porras JR; Gonzalez M; Garcia-Sanz R; San Miguel JF Thalidomide in combination with cyclophosphamide and dexamethasone (ThaCyDex) is effective in soft-tissue plasmacytomas | 0 | 0 |
| 1549 | 0 | 2 | 1409 2002 DEC [15] BRITISH JOURNAL OF PHARMACOLOGY 137 Paxton JW; Kestell P; Ding Q; Ching LM; Zhou S; Palmer BD; Baguley BC Preliminary investigations into the pharmacokinetic interaction between cyclophosphamide and thalidomide in the mouse | 0 | 0 |
| 1550 | 7 | 10 | 1510 2002 DEC [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1551 | 0 | 0 | 1516 2002 DEC [15] LANCET ONCOLOGY 3(12):711-711 Lindsey H Thalidomide plus dexamethasone for newly diagnosed myeloma | 0 | 0 |
| 1552 | 2 | 4 | 1527 2002 DEC [15] MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Crawford CL Thalidomide-induced neuropathy | 1 | 1 |
| 1553 | 2 | 2 | 1528 2002 DEC [15] MAYO CLINIC PROCEEDINGS 77(12):1395-1395 Rajkumar SV; Gertz MA; Kyle RA; Greipp PR Thalidomide-induced neuropathy - In reply | 0 | 0 |
| 1554 | 5 | 31 | 1551 2002 DEC [15] SEMINARS IN ONCOLOGY 29(6):34-38 Durie BGM Low-dose thalidomide in myeloma: Efficacy and biologic significance | 5 | 8 |
| 1555 | 13 | 29 | 1534 2002 DEC 24 NEUROLOGY 59(12):1872-1875 Chaudhry V; Cornblath DR; Corse A; Freimer M; Simmons-O'Brien E; Vogelsang G Thalidomide-induced neuropathy | 7 | 9 |
| 1556 | 7 | 22 | 1740 2003 JAN 1 JOURNAL OF CLINICAL ONCOLOGY 21(1):16-19 Weber D; Rankin K; Gavino M; Delasalle K; Alexanian R Thalidomide alone or with dexamethasone for previously untreated multiple myeloma | 32 | 59 |
| 1557 | 6 | 10 | 1801 2003 JAN 14 NEUROLOGY 60(1):130-132 Gupta A; Cohen BH; Ruggieri P; Packer RJ; Phillips PC Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1 | 1 | 4 |
| 1558 | 1 | 6 | 1564 2003 JAN [15] AMERICAN JOURNAL OF GASTROENTEROLOGY 98(1):221-222 Shurafa M; Kamboj G Thalidomide for the treatment of bleeding angiodysplasias | 1 | 2 |
| 1559 | 11 | 30 | 1588 2003 JAN [15] ARCHIVES OF DERMATOLOGY 139(1):50-54 Housman TS; Jorizzo JL; McCarty MA; Grummer SE; Fleischer AB; Sutej PG Low-dose thalidomide therapy for refractory cutaneous lesions of lupus erythematosus | 2 | 4 |
| 1560 | 19 | 50 | 1676 2003 JAN [15] BRITISH JOURNAL OF HAEMATOLOGY 120(1):18-26 Cavenagh JD; Oakervee H; UK Myeloma Forum; BSCH Haematology Oncology Task For Thalidomide in multiple myeloma: Current status and future prospects | 15 | 18 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1561 | 40 | 59 | 1709 2003 JAN [15] CURRENT OPINION IN DRUG DISCOVERY & DEVELOPMENT 6(1):92-99 Meierhofer C; Wiedermann CJ New insights into the pharmacological and toxicological effects of thalidomide | 3 | 3 |
| 1562 | 5 | 41 | 1734 2003 JAN [15] INTERNATIONAL JOURNAL OF ONCOLOGY 22(1):165-173 Yata K; Otsuki T; Kurebayashi J; Uno M; Fujii T; Yawata Y; Takata A; Hyodoh F; Sugihara T Expression of angiogenic factors including VEGFs and the effects of hypoxia and thalidomide on human myeloma cells | 2 | 3 |
| 1563 | 9 | 42 | 1751 2003 JAN [15] JOURNAL OF INTERFERON AND CYTOKINE RESEARCH 23(1):3-10 Bauer JA; Morrison BH; Grane RW; Jacobs BS; Borden EC; Lindner DJ IFN-alpha 2b and thalidomide synergistically inhibit tumor-induced angiogenesis | 0 | 2 |
| 1564 | 8 | 17 | 1779 2003 JAN [15] LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 8 | 17 |
| 1565 | 23 | 39 | 1796 2003 JAN [15] MAYO CLINIC PROCEEDINGS 78(1):34-39 Kumar S; Gertz MA; Dispenzieri A; Lacy MQ; Geyer SM; Iturria NL; Fonseca R; Hayman SR; Lust JA; Kyle RA; Greipp PR; Witzig TE; Rajkumar SV Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma | 9 | 21 |
| 1566 | 22 | 28 | 1692 2003 FEB 1 CANCER RESEARCH 63(3):593-599 Marriott JB; Clarke IA; Czajka A; Dredge K; Childs K; Man HW; Schafer P; Govinda S; Muller GW; Stirling DI; Dalgleish AG A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins | 7 | 14 |
| 1567 | 0 | 0 | 1767 2003 FEB 1 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
| 1568 | 2 | 29 | 1759 2003 FEB 5 JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 31(1):19-27 Li JY; Jaworsky MS; Stirling DI The determination of a potential impurity in Thalidomide drug substance and product by HPLC with indirect UV detection | 0 | 1 |
| 1569 | 69 | 104 | 1826 2003 FEB 8 SWISS MEDICAL WEEKLY 133(5-6):77-87 von Moos R; Stolz R; Cerny T; Gillessen S Thalidomide: from tragedy to promise | 1 | 1 |
| 1570 | 13 | 25 | 1589 2003 FEB [15] ARCHIVES OF DERMATOLOGY 139(2):136-138 Thomas P; Walchner M; Ghoreschi K; Rocken M Successful treatment of granulomatous cheilitis with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1571 | 0 | 0 | 1705 2003 FEB [15] CLINICAL PHARMACOLOGY & THERAPEUTICS 73(2):P55-P55 Gordon SM; Wahl SM; Picco C; Dionne RA Safety and tolerability and absorption of topical thalidomide. | 0 | 0 |
| 1572 | 156 | 221 | 1706 2003 FEB [15] CLINICAL THERAPEUTICS 25(2):342-395 Matthews SJ; McCoy C Thalidomide: A review of approved and investigational uses | 2 | 6 |
| 1573 | 0 | 0 | 1772 2003 FEB [15] LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 1574 | 57 | 70 | 1739 2003 FEB 25 JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES 785(1):165-173 Zhou SF; Lia Y; Kestell P; Paxton JW Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection | 0 | 0 |
| 1575 | 5 | 34 | 1689 2003 MAR 1 CANCER 97(5):1234-1241 Cortes J; Kantarjian H; Albitar M; Thomas D; Faderl S; Koller C; Garcia-Manero G; Giles F; Andreeff M; O'Brien S; Keating M; Estey E A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome | 2 | 7 |
| 1576 | 3 | 7 | 1802 2003 MAR 11 NEUROLOGY 60(5):877-878 Giannini F; Volpi N; Rossi S; Passero S; Fimiani M; Cerase A Thalidomide-induced neuropathy: a ganglionopathy? | 3 | 3 |
| 1577 | 0 | 0 | 1556 2003 MAR [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U196-U197 Hu ZG; Pandit B; Shi JD; Zink J; Sackett DL; Li PK Thalidomide analogs with antiproliferative and antimicrotubule activities. | 0 | 0 |
| 1578 | 0 | 0 | 1557 2003 MAR [15] ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 225:U197-U197 Luzzio FA; Ng SSW; Gutschow M; Hauschildt S; Weiss M; Teubert U; Kruger E; Mayorov AV; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogs. | 0 | 0 |
| 1579 | 11 | 28 | 1562 2003 MAR [15] ALIMENTARY PHARMACOLOGY & THERAPEUTICS 17(5):677-682 Khan ZH; Simpson EJ; Cole AT; Holt M; MacDonald I; Pye D; Austin A; Freeman JG Oesophageal cancer and cachexia: the effect of short-term treatment with thalidomide on weight loss and lean body mass | 0 | 1 |
| 1580 | 9 | 9 | 1578 2003 MAR [15] ANNALS OF ONCOLOGY 14(3):501-502 Trojan A; Chasse E; Gay B; Pichert G; Taverna C Severe hepatic toxicity due to thalidomide in relapsed multiple myeloma | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1581 | 0 | 0 | 1662 2003 MAR [15] BONE MARROW TRANSPLANTATION 31:S76-S77 Tueger S; Chen F; Ahsan G; Andrews V; Kazmi M; Madrigal J; Schey S Thalidomide-induced remission of refractory diffuse large B-cell lymphoma post-allogeneic SCT - a result of modulation of CTL function? | 0 | 0 |
| 1582 | 0 | 0 | 1663 2003 MAR [15] BONE MARROW TRANSPLANTATION 31:S78-S79 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fili C; Cerno M; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 1583 | 4 | 9 | 1672 2003 MAR [15] BRITISH JOURNAL OF DERMATOLOGY 148(3):601-602 Worm M; Kolde G Schnitzler's syndrome: successful treatment of two patients using thalidomide | 0 | 0 |
| 1584 | 4 | 12 | 1697 2003 MAR-APR [MAR 15] CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 21(2):272-272 Meaux-Ruault N; Magy N; Gil H; Dupond JL Efficacy of thalidomide in refractory adult Still's disease: A new case report | 0 | 0 |
| 1585 | 16 | 25 | 1702 2003 MAR [15] CLINICAL LYMPHOMA 3(4):241-246 Seldin DC; Choufani EB; Dember LM; Wiesman JF; Berk JL; Falk RH; O'Hara C; Fennessey S; Finn KT; Wright DG; Skinner M; Sanchorawala V Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis | 5 | 9 |
| 1586 | 9 | 21 | 1703 2003 MAR [15] CLINICAL LYMPHOMA 3(4):247-248 Blade J; Rosinol L Thalidomide: A step forward in the treatment of malignant monoclonal gammopathies | 0 | 0 |
| 1587 | 1 | 6 | 1718 2003 MAR [15] EUROPEAN JOURNAL OF HAEMATOLOGY 70(3):198-199 Vicari P; Ribas C; Sampaio M; Arantes AM; Yamamoto M; Reis JB; Segreto RA; Bordin JO; Colleoni GWB Can thalidomide be effective to treat plasma cell leptomeningeal infiltration? | 0 | 0 |
| 1588 | 19 | 40 | 1750 2003 MAR 15 JOURNAL OF INFECTIOUS DISEASES 187(6):946-955 Haslett PAJ; Hanekom WA; Muller G; Kaplan G Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8(+) T cells in vitro | 0 | 0 |
| 1589 | 6 | 10 | 1768 2003 MAR [15] JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 2 | 2 |
| 1590 | 8 | 21 | 1769 2003 MAR [15] JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):445-449 Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment | 2 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1591 | 15 | 21 | 1811 2003 MAR [15] PHARMACOTHERAPY 23(3):315-318 Horne MK; Figg WD; Arlen P; Gulley J; Parker C; Lakhani N; Parnes H; Dahut WL Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer | 3 | 4 |
| 1592 | 66 | 77 | 1814 2003 MAR [15] POSTGRADUATE MEDICAL JOURNAL 79(929):127-132 Gordon JN; Goggin PM Thalidomide and its derivatives: emerging from the wilderness | 0 | 3 |
| 1593 | 7 | 12 | 1825 2003 MAR-APR [MAR 15] SKIN PHARMACOLOGY AND APPLIED SKIN PHYSIOLOGY 16(2):123-129 Hadgraft J; Goosen C; du Plessis J; Flynn G Predicting the dermal absorption of thalidomide and its derivatives | 0 | 0 |
| 1594 | 8 | 20 | 1671 2003 MAR 24 BRITISH JOURNAL OF CANCER 88(6):822-827 Drake MJ; Robson W; Mehta P; Schofield I; Neal DE; Leung HY An open-label phase II study of low-dose thalidomide in androgen-independent prostate cancer | 4 | 10 |
| 1595 | 12 | 13 | 1788 2003 20030326-05:22:21 [MAR 26] LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
| 1596 | 1 | 6 | 1789 2003 20030326-05:22:21 [MAR 26] LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
| 1597 | 15 | 47 | 1602 2003 APR 1 BLOOD 101(7):2534-2541 Mesa RA; Steensma DP; Pardanani A; Li CY; Elliott M; Kaufmann SH; Wiseman G; Gray LA; Schroeder GE; Reeder T; Zeldis JB; Tefferi A A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia | 6 | 10 |
| 1598 | 0 | 0 | 1721 2003 APR 14 FASEB JOURNAL 17(7):C124-C124 Dredge K; Marriott JB; Todryk SM; Klaschka D; Horsfall R; Dalgleish A The role of thalidomide-related IMiDs in the induction of innate and adaptive anti-tumor immunity | 0 | 0 |
| 1599 | 5 | 6 | 1572 2003 APR [15] ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 130(4):489-489 Schmutz JL; Barbaud A; Trechot P Thalidomide and thrombosis | 0 | 0 |
| 1600 | 2 | 5 | 1575 2003 APR [15] ANNALS OF HEMATOLOGY 82(4):262-262 Ribatti A; Vacca A On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1601 | 10 | 33 | 1579 2003 APR [15] ANNALS OF PHARMACOTHERAPY 37(4):571-576 Thompson JL; Hansen LA Thalidomide dosing in patients with relapsed or refractory multiple myelorna | 0 | 0 |
| 1602 | 0 | 0 | 1601 2003 APR [15] BIOTECHNOLOGY LAW REPORT 22(2):120-120 [Anon] Celgene, EntreMed agree to license for thalidomide analog - Companies will drop their infringement suits | 0 | 0 |
| 1603 | 5 | 12 | 1677 2003 APR [15] BRITISH JOURNAL OF HAEMATOLOGY 121(1):101-103 Steurer M; Sudmeier I; Stauder R; Gastl G Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha | 5 | 7 |
| 1604 | 3 | 5 | 1678 2003 APR [15] BRITISH JOURNAL OF HAEMATOLOGY 121(1):191-192 Younis TH Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma | 1 | 2 |
| 1605 | 2 | 3 | 1711 2003 APR [15] DIABETES CARE 26(4):1322-1323 Pathak RD; Jayaraj K; Blonde L Thalidomide-associated hyperglycemia and diabetes - Case report and review of literature | 0 | 0 |
| 1606 | 16 | 37 | 1713 2003 APR [15] DRUG METABOLISM AND DISPOSITION 31(4):469-475 Miyata M; Tamura E; Motoki K; Nagata K; Yamazoe Y Thalidomide-induced suppression of embryo fibroblast proliferation requires CYP1A1-mediated activation | 2 | 2 |
| 1607 | 0 | 0 | 1722 2003 APR [15] GASTROENTEROLOGY 124(4):A10-A10 Jin SH; Kim WH; Kim TI; Yang KM; Shin SK; Lee SK; Park SJ; Choi CH; Lee WJ Thalidomide destabilizes cyclooxygenase-2 mRNA by inhibiting p38 mitogen-activated protein kinase and cytoplasmic shuttling of HuR | 0 | 0 |
| 1608 | 0 | 0 | 1723 2003 APR [15] GASTROENTEROLOGY 124(4):A336-A336 Kim YS; Kim JS; Jung HC; Song IS The effects of thalidomide on NF-R activity and TNF-production stimulated with lipopolysaccharide in a human colonic epithelial cell line ka | 0 | 0 |
| 1609 | 0 | 0 | 1724 2003 APR [15] GASTROENTEROLOGY 124(4):A525-A525 Gupta P; Andrew H; Kirschner BS Thalidomide therapy for pediatric patients with refractory Crohn's disease not responding to infliximab | 0 | 0 |
| 1610 | 4 | 9 | 1737 2003 APR [15] JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 9(2):96-98 Ching DWT; McClintock A; Beswick F Successful treatment with low-dose thalidomide in a patient with both Behcet's disease and complex regional pain syndrome type I - Case report | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1611 | 10 | 14 | 1763 2003 APR [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
| 1612 | 0 | 0 | 1771 2003 APR [15] JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
| 1613 | 12 | 32 | 1780 2003 APR [15] LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 12 | 19 |
| 1614 | 1 | 11 | 1797 2003 APR [15] MEDICAL HYPOTHESES 60(4):513-514 Namazi MR The potential efficacy of thalidomide in the treatment of recalcitrant alopecia areata | 0 | 0 |
| 1615 | 41 | 78 | 1812 2003 APR [15] PHARMACOTHERAPY 23(4):481-493 Okafor MC Thalidomide for erythema nodosum leprosum and other applications | 0 | 0 |
| 1616 | 6 | 25 | 1823 2003 APR [15] SEMINARS IN ONCOLOGY 30(2):265-269 Dimopoulos MA; Tsatalas C; Zomas A; Hamilos G; Panayiotidis P; Margaritis D; Matsouka C; Economopoulos T; Anagnostopoulos N Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone | 3 | 5 |
| 1617 | 7 | 29 | 1824 2003 APR [15] SEMINARS IN ONCOLOGY 30(2):270-274 Coleman M; Leonard J; Lyons L; Szelenyi H; Niesvizky R Treatment of Waldenstrom's macroglobulinemia with clarithromycin, low-dose thalidomide, and dexamethasone | 3 | 6 |
| 1618 | 1 | 2 | 1798 2003 APR 21 MEDICAL JOURNAL OF AUSTRALIA 178(8):413-413 Elwood JM Thalidomide and cancer? | 0 | 0 |
| 1619 | 2 | 3 | 1803 2003 MAY 1 NEW ENGLAND JOURNAL OF MEDICINE 348(18):1821-1822 Morgan AE; Smith WK; Levenson JL Reversible dementia due to thalidomide therapy for multiple myeloma | 1 | 1 |
| 1620 | 3 | 37 | 1565 2003 MAY [15] AMERICAN JOURNAL OF HEMATOLOGY 73(1):48-53 Lee FC; Merchant SH Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide | 1 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1621 | 12 | 27 | 1583 2003 MAY-JUN [MAY 15] ANTICANCER RESEARCH 23(3B):2405-2411 Fujii T; Tachibana M; Dhar DK; Ueda S; Kinugasa S; Yoshimura H; Kohno H; Nagasue N Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice | 0 | 0 |
| 1622 | 6 | 17 | 1584 2003 MAY-JUN [MAY 15] ANTICANCER RESEARCH 23(3B):2481-2487 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells | 0 | 0 |
| 1623 | 0 | 4 | 1592 2003 MAY [15] ARCHIVOS DE BRONCONEUMOLOGIA 39(5):240-240 Garcia BD; Gafas AD; Alvarez MJF Lung toxicity due to thalidomide | 0 | 0 |
| 1624 | 5 | 11 | 1673 2003 MAY [15] BRITISH JOURNAL OF DERMATOLOGY 148(5):1060-1061 Tjiu JW; Hsiao CH; Tsai TF Cutaneous Rosai-Dorfman disease: remission with thalidomide treatment | 0 | 0 |
| 1625 | 26 | 38 | 1698 2003 MAY [15] CLINICAL CANCER RESEARCH 9(5):1680-1688 Lu J; Palmer BD; Kestell P; Browett P; Baguley BC; Muller G; Ching LM Thalidomide metabolites in mice and patients with multiple myeloma | 7 | 8 |
| 1626 | 0 | 0 | 1716 2003 MAY [15] EUROPEAN JOURNAL OF CANCER 39(7):854-854 [Anon] Thalidomide on trial | 0 | 0 |
| 1627 | 3 | 10 | 1725 2003 MAY [15] HAEMATOLOGICA 88(5):597-599 Patriarca F; Sperotto A; Prosdocimo S; Geromin A; Zaja F; Fanin R Thalidomide before autologous stem cell transplantation in VAD-refractory multiple myeloma patients | 0 | 0 |
| 1628 | 11 | 39 | 1731 2003 MAY [15] INTERNATIONAL JOURNAL OF DERMATOLOGY 42(5):372-375 Alfadley A; Al-Hawsawi K; Thestrup-Pedersen K; Al-Aboud K Treatment of prurigo nodularis with thalidomide: a case report and review of the literature | 0 | 0 |
| 1629 | 9 | 12 | 1764 2003 MAY [15] JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
| 1630 | 11 | 52 | 1765 2003 MAY-JUN [MAY 15] JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1631 | 44 | 67 | 1806 2003 MAY [15] ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY AND ENDODONTICS 95(5):576-585 Hegarty A; Hodgson T; Porter S Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis | 1 | 2 |
| 1632 | 4 | 19 | 1827 2003 20030527-21:08:57 [MAY 27] SYNTHETIC COMMUNICATIONS 33(8):1375-1382 Chang MY; Chen ST; Chang NC A synthesis of racemic thalidomide | 0 | 4 |
| 1633 | 6 | 15 | 1741 2003 JUN 1 JOURNAL OF CLINICAL ONCOLOGY 21(11):2211-2214 Loprinzi C; Rajkumar SV Why not start with thalidomide? | 0 | 1 |
| 1634 | 5 | 9 | 1559 2003 20030604-09:41:54 [JUN 04] ACTA HAEMATOLOGICA 109(3):153-155 Tsiara S; Chaidos A; Kapsali H; Tzouvara E; Bourantas KL Thalidomide administration for the treatment of resistant plasma cell leukemia | 0 | 0 |
| 1635 | 22 | 30 | 1582 2003 JUN [15] ANTI-CANCER DRUGS 14(5):331-335 Dredge K; Dalgleish AG; Marriott JB Thalidomide analogs as emerging anti-cancer drugs | 3 | 8 |
| 1636 | 1 | 5 | 1593 2003 JUN [15] ARCHIVOS DE BRONCONEUMOLOGIA 39(6):286-286 Valero FC Lung toxicity due to thalidomide | 0 | 0 |
| 1637 | 2 | 6 | 1664 2003 JUN [15] BONE MARROW TRANSPLANTATION 31(11):1065-1065 Pitini V; Arrigo C; Aloi G; Micali C; La Gattuta G Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT | 0 | 0 |
| 1638 | 0 | 1 | 1665 2003 JUN [15] BONE MARROW TRANSPLANTATION 31(11):1067-1067 Alam AR Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT - Reply to the letter by V Pitini | 0 | 0 |
| 1639 | 4 | 12 | 1679 2003 JUN [15] BRITISH JOURNAL OF HAEMATOLOGY 121(5):768-771 Anagnostopoulos A; Weber D; Rankin K; Delasalle K; Alexanian R Thalidomide and dexamethasone for resistant multiple myeloma | 11 | 16 |
| 1640 | 19 | 31 | 1693 2003 JUN 15 CANCER RESEARCH 63(12):3189-3194 Ng SSW; Gutschow M; Weiss M; Hauschildt S; Teubert U; Hecker TK; Luzzio FA; Kruger EA; Eger K; Figg WD Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues | 4 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1641 | 4 | 20 | 1704 2003 JUN [15] CLINICAL LYMPHOMA 4(1):32-35 Zangari M; Barlogie B; Thertulien R; Jacobson J; Eddleman P; Fink L; Fassas A; Van Rhee F; Talamo G; Lee CK; Tricot G Thalidomide and deep vein thrombosis in multiple myeloma: Risk factors and effect on survival | 3 | 6 |
| 1642 | 7 | 20 | 1733 2003 JUN [15] INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 11(6):785-790 Li XP; Liu XY; Wang J; Wang ZL; Jiang W; Reed E; Zhang Y; Liu YL; Li QQ Effects of thalidomide on the expression of angiogenesis growth factors in human A(549) lung adenocarcinoma cells | 0 | 0 |
| 1643 | 4 | 37 | 1742 2003 JUN 15 JOURNAL OF CLINICAL ONCOLOGY 21(12):2299-2304 Fine HA; Wen PY; Maher EA; Viscosi E; Batchelor T; Lakhani N; Figg WD; Purow BW; Borkowf CB Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas | 2 | 5 |
| 1644 | 9 | 39 | 1760 2003 JUN [15] JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
| 1645 | 5 | 8 | 1781 2003 JUN [15] LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
| 1646 | 35 | 95 | 1817 2003 JUN [15] SCHMERZ 17(3):204-+ Peuckmann V; Strumpf M; Zenz M; Bruera E Novel potential uses of thalidomide in the management of pain? A review of the literature | 0 | 0 |
| 1647 | 11 | 18 | 1710 2003 20030620-19:10:16 [JUN 20] DERMATOLOGY 206(4):381-383 Kolivras A; De Maubeuge J; Andre J; Song M Thalidomide in refractory vulvar ulcerations associated with Crohn's disease | 1 | 1 |
| 1648 | 2 | 7 | 1590 2003 JUN 23 ARCHIVES OF INTERNAL MEDICINE 163(12):1487-1488 Schwartzman R; Chevlen E; Bengtson K Thalidomide has activity in treating complex regional pain syndrome | 0 | 0 |
| 1649 | 1 | 1 | 1591 2003 JUN 23 ARCHIVES OF INTERNAL MEDICINE 163(12):1488-1488 Rajkumar SV; Fonseca R; Witzig TE Thalidomide has activity in treating complex regional pain syndrome - Reply | 0 | 0 |
| 1650 | 49 | 86 | 1707 2003 JUN 27 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S49-S57 Macpherson GR; Franks M; Tomoaia-Cotisel A; Ando Y; Price DK; Figg WD Current status of thalidomide and its role in the treatment of metastatic prostate cancer | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1651 | 13 | 38 | 1708 2003 JUN 27 CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 46:S59-S65 Amato RJ Thalidomide therapy for renal cell carcinoma | 0 | 1 |
| 1652 | 0 | 4 | 1603 2003 JUL 1 BLOOD 102(1):2-3 Hussein MA Thalidomide, age, and future use in multiple myeloma | 0 | 0 |
| 1653 | 18 | 42 | 1604 2003 JUL 1 BLOOD 102(1):69-77 Mileshkin L; Biagi JJ; Mitchell P; Underhill C; Grigg A; Bell R; McKendrick J; Briggs P; Seymour JF; Lillie K; Smith JG; Zeldis JB; Prince HM Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age | 7 | 10 |
| 1654 | 5 | 37 | 1743 2003 JUL 1 JOURNAL OF CLINICAL ONCOLOGY 21(13):2551-2557 Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma | 2 | 7 |
| 1655 | 7 | 17 | 1586 2003 20030710-02:00:52 [JUL 10] APMIS 111:113-116 Chew M; Zhou J; Daugherty A; Eriksson T; Ellermann-Eriksen S; Hansen PR; Falk E Thalidomide inhibits early atherogenesis in apoE-deficient mice | 0 | 0 |
| 1656 | 8 | 19 | 1580 2003 JUL-AUG [JUL 15] ANNALS OF PHARMACOTHERAPY 37(7-8):1040-1043 Kaur A; Yu SS; Lee AJ; Chiao TB Thalidomide-induced sinus bradycardia | 1 | 1 |
| 1657 | 13 | 35 | 1666 2003 JUL [15] BONE MARROW TRANSPLANTATION 32(2):165-170 Kulkarni S; Powles R; Sirohi B; Treleaven J; Saso R; Horton C; Atra A; Ortin M; Rudin C; Goyal S; Sankpal S; Meller S; Pinkerton CR; Mehta J; Singhal S Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease | 1 | 2 |
| 1658 | 0 | 0 | 1669 2003 JUL [15] BRITISH JOURNAL OF CANCER 88:S28-S28 Dalgleish A; Schey S; Jones R; Raj K; Dredge K; Streetly M; Marriott B Thalidomide analogues CC-5013 and CC-4047 induce T cell activation and IL-12 production in patients with both solid tumours and relapsed and refractory multiple myeloma. | 0 | 0 |
| 1659 | 0 | 0 | 1670 2003 JUL [15] BRITISH JOURNAL OF CANCER 88:S46-S46 Malpas J; Chaplin T; Sanmugathasan A; Liu W In vitro activity of S-thalidomide against multiple myeloma cells: A gene and protein expression profile. | 0 | 0 |
| 1660 | 0 | 0 | 1674 2003 JUL [15] BRITISH JOURNAL OF DERMATOLOGY 149:81-81 Strauss RM; Bate J; Clayton T; Gooi J; Darling J; Newton-Bishop JA A child with laryngo-onycho-cutaneous syndrome successfully treated with thalidomide | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1661 | 4 | 7 | 1680 2003 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 122(1):159-160 Santos AB; Llamas P; Roman A; Prieto E; de Ona R; de Velasco JF; Tomas JF Evaluation of thrombophylic states in myeloma patients receiving thalidomide: A reasonable doubt | 2 | 2 |
| 1662 | 5 | 6 | 1681 2003 JUL [15] BRITISH JOURNAL OF HAEMATOLOGY 122(1):160-161 Harris E; Behrens J; Samson D; Rahemtulla A; Russell NH; Byrne JL Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia | 2 | 3 |
| 1663 | 5 | 27 | 1690 2003 JUL [15] CANCER CHEMOTHERAPY AND PHARMACOLOGY 52:S16-S23 Hashimoto Y Structural development of synthetic retinoids and thalidomide-related molecules | 0 | 0 |
| 1664 | 0 | 0 | 1719 2003 JUL [15] EXPERIMENTAL HEMATOLOGY 31(7):198-198 Moutouh-De Parseval L; Glezer E; Corral L; Galliher A; Wu J; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cell developmental pathways | 0 | 0 |
| 1665 | 73 | 144 | 1720 2003 JUL [15] EXPERT OPINION ON INVESTIGATIONAL DRUGS 12(7):1211-1225 Fanelli M; Sarmiento R; Gattuso D; Carillio G; Capaccetti B; Vacca A; Roccaro AM; Gasparini G Thalidomide: a new anticancer drug? | 3 | 7 |
| 1666 | 6 | 15 | 1728 2003 JUL [15] INTERNAL MEDICINE 42(7):550-551 Dan K Thalidomide as a targeted therapy for multiple myeloma | 0 | 0 |
| 1667 | 5 | 10 | 1729 2003 JUL [15] INTERNAL MEDICINE 42(7):605-608 Hayashi T; Yamaguchi I; Saitoh H; Takagi M; Nonaka Y; Nomura T Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis | 1 | 2 |
| 1668 | 7 | 25 | 1744 2003 JUL 15 JOURNAL OF CLINICAL ONCOLOGY 21(14):2732-2739 Lee CK; Barlogie B; Munshi N; Zangari M; Fassas A; Jacobson J; van Rhee F; Cottler-Fox M; Muwalla F; Tricot G DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma | 4 | 11 |
| 1669 | 1 | 27 | 1753 2003 JUL [15] JOURNAL OF MEDICAL GENETICS 40(7):473-478 Kohlhase J; Schubert L; Liebers M; Rauch A; Becker K; Mohammed SN; Newbury-Ecob R; Reardon W Mutations at the SALL4 locus on chromosome 20 result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and patients previously reported to represent thalidomide embryopathy | 1 | 6 |
| 1670 | 26 | 38 | 1790 2003 JUL [15] LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1671 | 12 | 17 | 1791 2003 JUL [15] LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
| 1672 | 2 | 8 | 1558 2003 20030805-19:16:58 [AUG 05] ACTA DERMATO-VENEREOLOGICA 83(4):302-303 Staumont-Salle D; Magro L; Piette F; Thomas P; Jouet JP; Catteau B Chronic graft-versus-host disease revealed by lichenoid vulvar lesions successfully treated with thalidomide | 0 | 0 |
| 1673 | 19 | 25 | 1807 2003 AUG 7 ORGANIC LETTERS 5(16):2865-2867 Capitosti SM; Hansen TP; Brown ML Facile synthesis of an azido-labeled thalidomide analogue | 0 | 2 |
| 1674 | 7 | 31 | 1561 2003 AUG [15] ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH 27(8):2S-6S Enomoto N; Takei Y; Hirose M; Kitamura T; Ikejima K; Sato N Protective effect of thalidomide on endotoxin-induced liver injury | 0 | 1 |
| 1675 | 14 | 24 | 1585 2003 AUG [15] ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 47(8):2445-2449 Giamarellos-Bourboulis EJ; Poulaki H; Kostomitsopoulos N; Dontas I; Perrea D; Karayannacos PE; Giamarellou H Effective immunomodulatory treatment of Escherichia coli experimental sepsis with thalidomide | 0 | 1 |
| 1676 | 6 | 6 | 1667 2003 AUG [15] BONE MARROW TRANSPLANTATION 32(3):343-343 Milone JH; Prates V; Bordone J; Napal J; Garcia C Response to single-agent thalidomide and eligibility to undergo autotransplant for patients with multiple myeloma refractory to VAD | 0 | 0 |
| 1677 | 11 | 14 | 1675 2003 AUG [15] BRITISH JOURNAL OF DERMATOLOGY 149(2):432-433 Dobson CM; Parslew RA Exacerbation of psoriasis by thalidomide in Behcet's syndrome | 0 | 0 |
| 1678 | 19 | 40 | 1682 2003 AUG [15] BRITISH JOURNAL OF HAEMATOLOGY 122(4):607-616 Kropff MH; Lang N; Bisping G; Domine N; Innig G; Hentrich M; Mitterer M; Sudhoff T; Fenk R; Straka C; Heinecke A; Koch OM; Ostermann H; Berdel WE; Kienast J Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma | 5 | 9 |
| 1679 | 5 | 10 | 1714 2003 AUG [15] DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Zhou SF CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation | 0 | 0 |
| 1680 | 0 | 0 | 1715 2003 AUG [15] DRUG METABOLISM AND DISPOSITION 31(8):1072-1072 Miyata M CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1681 | 4 | 10 | 1726 2003 AUG [15] HAEMATOLOGICA 88(8):958-960 Corso A; Lorenzi A; Zapposodi P; Invernizzi R; Vanelli L; Lazzarino M Early changes in bone marrow morphology induced by thalidomide in patients with refractory myeloma | 0 | 0 |
| 1682 | 14 | 32 | 1736 2003 AUG [15] INVESTIGATIONAL NEW DRUGS 21(3):359-366 Dal Lago L; Richter MF; Cancela AI; Fernandes SA; Jung KT; Rodrigues AC; Dalla Costa T; Di Leone LP; Schwartsmann G Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer | 1 | 1 |
| 1683 | 5 | 8 | 1782 2003 AUG [15] LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
| 1684 | 12 | 35 | 1800 2003 AUG [15] MOLECULAR PHARMACOLOGY 64(2):415-420 Drucker L; Uziel O; Tohami T; Shapiro H; Radnay J; Yarkoni S; Lahav M; Lishner M Thalidomide down-regulates transcript levels of GC-rich promoter genes in multiple myeloma | 0 | 1 |
| 1685 | 1 | 26 | 1809 2003 AUG [15] PEDIATRIC NEUROLOGY 29(2):151-156 Marjanovic BD; Stojanov LM; Zdravkovic DS; Kravljanac RM; Djordjevic MS Rasmussen syndrome and long-term response to thalidomide | 0 | 0 |
| 1686 | 10 | 48 | 1816 2003 AUG [15] RHEUMATIC DISEASE CLINICS OF NORTH AMERICA 29(3):481-+ Davis JC; Huang F; Maksymowych W New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate | 0 | 0 |
| 1687 | 11 | 25 | 1754 2003 AUG 28 JOURNAL OF MEDICINAL CHEMISTRY 46(18):3793-3799 Luzzio FA; Mayorov AV; Ng SSW; Kruger EA; Figg WD Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNF alpha-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine | 1 | 1 |
| 1688 | 8 | 11 | 1560 2003 20030829-21:21:05 [AUG 29] ADAMANTIADES-BEHCET'S DISEASE 528:585-589 Sohn S; Lee ES; Lee SI; Kim YA; Kwon HJ; Bang D; Lei S Therapeutic effect of thalidomide through cytokine and chemokine regulation in herpes simplex virus-induced Behcet's disease-like animal model | 0 | 0 |
| 1689 | 7 | 26 | 1745 2003 SEP 1 JOURNAL OF CLINICAL ONCOLOGY 21(17):3351-3356 Hwu WJ; Krown SE; Menell JH; Panageas KS; Merrell J; Lamb LA; Williams LJ; Quinn CJ; Foster T; Chapman PB; Livingston PO; Wolchok JD; Houghton AN Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma | 4 | 14 |
| 1690 | 1 | 10 | 1570 2003 SEP [15] AMERICAN JOURNAL OF MEDICINE 115(4):332-334 Staak JO; Glossmann JP; Esser JM; Diehl V; Mietz H; Josting A Thalidomide for systemic capillary leak syndrome | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1691 | 27 | 37 | 1576 2003 SEP [15] ANNALS OF HEMATOLOGY 82(9):558-564 Huang SY; Tang JL; Yao M; Ko BS; Hong RL; Tsai W; Wang CH; Tien HF; Shen MC; Chen YC Reduction of leukocyte count is associated with thalidomide response in treatment of multiple myeloma | 0 | 0 |
| 1692 | 151 | 187 | 1581 2003 SEP [15] ANNALS OF PHARMACOTHERAPY 37(9):1307-1320 Nasca MR; Micali G; Cheigh NH; West LE; West DP Dermatologic and nondermatologic uses of thalidomide | 1 | 1 |
| 1693 | 0 | 0 | 1594 2003 SEP [15] ARTHRITIS AND RHEUMATISM 48(9):S92-S92 Schechter SJ; Sundel R; Oliveira SK; Huttenlocher A; Onel K; Lehman TJA Thalidomide for severe systemic onset JIA. | 0 | 0 |
| 1694 | 0 | 0 | 1595 2003 SEP [15] ARTHRITIS AND RHEUMATISM 48(9):S587-S587 Doria A; Briani C; Zara G; Rondinone R; Ermani M; Della Libera S; Ghirardello A; Zampieri S; Tedesco S Prospective study on thalidomide-induced peripheral neuropathy in SLE. | 0 | 0 |
| 1695 | 0 | 0 | 1596 2003 SEP [15] ARTHRITIS AND RHEUMATISM 48(9):S588-S589 Vazquez-Cobian LB; Onel KB; Lehman TJA Thalidomide in systemic lupus erythematosus. | 0 | 0 |
| 1696 | 0 | 0 | 1597 2003 SEP [15] ARTHRITIS AND RHEUMATISM 48(9):S617-S617 Efthimiou P; Rosenkranz ME; Mackenzie R; Adler R; Paget SA IVIG and thalidomide combination is an effective novel therapy for scleromyxedema. | 0 | 0 |
| 1697 | 0 | 0 | 1598 2003 SEP [15] ATHEROSCLEROSIS SUPPLEMENTS 4(2):28-28 Park SJ Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery | 0 | 0 |
| 1698 | 11 | 28 | 1668 2003 SEP [15] BONE MARROW TRANSPLANTATION 32(6):587-592 Ghobrial IM; Dispenzieri A; Bundy KL; Gastineau DA; Rajkumar SV; Therneau TM; Lacy MQ; Witzig TE; Litzow MR; Christensen BR; Hayman S; Pribula CG; Gertz MA Effect of thalidomide on stem cell collection and engraftment in patients with multiple myeloma | 1 | 1 |
| 1699 | 9 | 31 | 1695 2003 SEP [15] CHEMICAL & PHARMACEUTICAL BULLETIN 51(9):1098-1102 Suizu M; Muroya Y; Kakuta H; Kagechika H; Tanatani A; Nagasawa K; Hashimoto Y Cyclooxygenase inhibitors derived from thalidomide | 3 | 3 |
| 1700 | 12 | 33 | 1717 2003 SEP [15] EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY 15(9):951-957 Muriel P; Fernandez-Martinez E; Perez-Alvarez V; Lara-Ochoa F; Ponce S; Garcia J; Shibayama M; Tsutsumi V Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1701 | 0 | 0 | 1738 2003 SEP [15] JOURNAL OF BONE AND MINERAL RESEARCH 18:S310-S310 Bose N; Bergemann H; Westendorf JJ; Rajkumar SV; Masellis AM Expression of alternatively spliced Runx2 in multiple myeloma patients and a shift in expression in response to thalidomide treatment. | 0 | 0 |
| 1702 | 10 | 26 | 1756 2003 SEP [15] JOURNAL OF NEURO-ONCOLOGY 64(3):193-201 Gelati M; Corsini E; Frigerio S; Pollo B; Broggi G; Croci D; Silvani A; Boiardi A; Salmaggi A Effects of thalidomide on parameters involved in angiogenesis: an in vitro study | 0 | 1 |
| 1703 | 9 | 20 | 1774 2003 SEP [15] LEPROSY REVIEW 74(3):206-214 Tadesse A; Taye E; Sandoval F; Shannow EJ Thalidomide does not modify the ability of cells in leprosy patients to incorporate [H-3]-thymidine when incubated with M-leprae antigens | 0 | 0 |
| 1704 | 2 | 20 | 1775 2003 SEP [15] LEPROSY REVIEW 74(3):286-288 Pannikar V The return of thalidomide: new uses and renewed concerns | 0 | 1 |
| 1705 | 5 | 32 | 1776 2003 SEP [15] LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
| 1706 | 2 | 28 | 1777 2003 SEP [15] LEPROSY REVIEW 74(3):290-294 Lockwood D; Bryceson A The return of thalidomide: new uses and renewed concerns - reply | 0 | 2 |
| 1707 | 0 | 0 | 1778 2003 SEP [15] LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
| 1708 | 10 | 11 | 1783 2003 SEP [15] LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
| 1709 | 19 | 36 | 1792 2003 SEP [15] LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
| 1710 | 12 | 18 | 1793 2003 SEP [15] LEUKEMIA & LYMPHOMA 44(11):1943-1946 Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Low dose thalidomide in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1711 | 0 | 0 | 1810 2003 SEP [15] PHARMACOPSYCHIATRY 36(5):263-264 Schuld A; Hinze-Selch D; Haack M; Dalal MA; Himmerich H; Lancel M; Pollmacher T Sleep changes following chlorpromazine, clozapine, olanzapine or thalidomide in healthy subjects - First results from a double-blind, placebocontrolled study | 0 | 0 |
| 1712 | 12 | 23 | 1829 2003 SEP [15] XENOTRANSPLANTATION 10(5):470-474 Yamamoto S; Cooper DKC An investigation of the effect of thalidomide on anti-gal antibody production in baboons | 0 | 0 |
| 1713 | 6 | 10 | 1795 2003 20030929-19:54:46 [SEP 29] LUPUS 12(9):723-724 Tektonidou MG; Vlachoyiannopoulos PG Antiphospholipid syndrome triggered by thalidomide in a patient with discoid lupus erythematosus | 0 | 0 |
| 1714 | 0 | 1 | 1688 2003 OCT 4 BRITISH MEDICAL JOURNAL 327(7418):767-767 Burgermeister J Head of German medicines body likens HRT to thalidomide | 0 | 0 |
| 1715 | 11 | 22 | 1808 2003 20031007-20:01:23 [OCT 07] PATHOPHYSIOLOGY OF HAEMOSTASIS AND THROMBOSIS 33:15-18 Rodeghiero F; Elice F Thalidomide and thrombosis | 1 | 2 |
| 1716 | 9 | 33 | 1577 2003 OCT [15] ANNALS OF HEMATOLOGY 82(10):654-659 Goldschmidt H; Sonneveld P; Cremer FW; van der Holt B; Westveer P; Breitkreutz I; Benner A; Glasmacher A; Schmidt-Wolf IGD; Martin H; Hoelzer D; Ho AD; Lokhorst HM Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients | 0 | 0 |
| 1717 | 10 | 16 | 1587 2003 OCT [15] ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX 96(10):1006-1010 Jego C; Barbou F; Laurent P; Gisserot O; Cellarier G; Bonal J; Bouchiat C; Landais C; de Jaureguiberry JP; Dussarat GV Left atrial thrombus in the course of multiple myeloma treated with thalidomide | 0 | 0 |
| 1718 | 4 | 10 | 1683 2003 OCT [15] BRITISH JOURNAL OF HAEMATOLOGY 123(2):305-308 Thompson MA; Witzig TE; Kumar S; Timm MM; Haug J; Fonseca R; Greipp PR; Lust JA; Rajkumar SV Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myeloma | 2 | 4 |
| 1719 | 16 | 42 | 1730 2003 OCT [15] INTERNATIONAL IMMUNOPHARMACOLOGY 3(10-11):1447-1456 Karrow NA; Guo TL; Zhang LX; McCay JA; Musgrove DL; Peachee VL; Germolec DR; White KL Thalidomide modulation of the immune response in female B6C3F1 mice: a host resistance study | 0 | 1 |
| 1720 | 13 | 36 | 1746 2003 OCT 15 JOURNAL OF CLINICAL ONCOLOGY 21(20):3770-3776 Hernberg M; Virkkunen P; Bono P; Atinen H; Maenpaa H; Joensuu H Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma | 2 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1721 | 10 | 16 | 1749 2003 OCT [15] JOURNAL OF INFECTION 47(3):251-255 Roberts MTM; Mendelson M; Meyer P; Carmichael A; Lever AML The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports | 0 | 0 |
| 1722 | 4 | 4 | 1757 2003 OCT [15] JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION 37(4):522-522 Ahmed M; El-Hadi S; Jenkins HR Thalidomide in Crohn disease and the risk of peripheral neuropathy | 0 | 0 |
| 1723 | 3 | 8 | 1784 2003 OCT [15] LEUKEMIA 17(10):2056-2057 Dalle JH; Leblond P; Decouvelaere A; Yakoub-Agha I; Preudhomme C; Nelken B; Mazingue F Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL | 0 | 0 |
| 1724 | 12 | 27 | 1794 2003 OCT [15] LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 2 | 3 |
| 1725 | 7 | 20 | 1818 2003 OCT [15] SEMINARS IN HEMATOLOGY 40(4):1-2 Barlogie B Introduction: Thalidomide and the IMiDs in multiple myeloma | 0 | 0 |
| 1726 | 12 | 17 | 1819 2003 OCT [15] SEMINARS IN HEMATOLOGY 40(4):3-7 Alexanian R; Weber D; Anagnostopoulos A; Delasalle K; Wang M; Rankin K Thalidomide with or without dexamethasone for refractory or relapsing multiple myeloma | 0 | 0 |
| 1727 | 14 | 23 | 1820 2003 OCT [15] SEMINARS IN HEMATOLOGY 40(4):8-16 Dimopoulos MA; Anagnostopoulos A Thalidomide in relapsed/refractory multiple myeloma: Pivotal trials conducted outside the United States | 0 | 0 |
| 1728 | 10 | 33 | 1821 2003 OCT [15] SEMINARS IN HEMATOLOGY 40(4):17-22 Rajkumar SV Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease | 0 | 0 |
| 1729 | 11 | 14 | 1822 2003 OCT [15] SEMINARS IN HEMATOLOGY 40(4):33-38 Barlogie B Thalidomide and CC-5013 in multiple myeloma: The University of Arkansas experience | 0 | 0 |
| 1730 | 6 | 25 | 1828 2003 OCT [15] WORLD JOURNAL OF SURGERY 27(10):1119-1123 Mall JW; Schwenk W; Philipp AW; Buttemeyer R; Pollmann C Intraperitoneal administration of the angiogenesis inhibitor thalidomide does not impair anastomotic healing following large bowel resection in a rabbit model | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1731 | 43 | 65 | 1563 2003 20031020-20:33:38 [OCT 20] AMERICAN JOURNAL OF CLINICAL DERMATOLOGY 4(6):379-387 Pelle MT; Werth VP Thalidomide in cutaneous lupus erythematosus | 0 | 0 |
| 1732 | 12 | 26 | 1600 2003 OCT 20 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 13(20):3415-3417 Man HW; Corral LG; Stirling DI; Muller GW alpha-fluoro-substituted thalidomide analogues | 1 | 1 |
| 1733 | 0 | 0 | 1696 2003 OCT 28 CIRCULATION 108(17):170-170 Kirchmair R; Murayama T; Rittig K; Tietz A; Walter D; Schratzberger P; Weinberg DH; Ropper AH; Isner JM Therapeutic angiogenesis inhibits and rescues chemotherapy induced peripheral neuropathy: Taxol, cisplatin and thalidomide induced injury vasa nervorum is ameliorated by VEGF gene therapy | 0 | 0 |
| 1734 | 0 | 0 | 1699 2003 NOV 1 CLINICAL CANCER RESEARCH 9(14):5429-5429 Ching LM; Baguley BC; Kestell P; Palmer BD; Lu J Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. - Reply | 0 | 0 |
| 1735 | 8 | 8 | 1700 2003 NOV 1 CLINICAL CANCER RESEARCH 9(14):5429-5429 Zhou SF Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9 : 1680-1688, 2003. | 0 | 0 |
| 1736 | 3 | 10 | 1566 2003 NOV [15] AMERICAN JOURNAL OF HEMATOLOGY 74(3):205-207 Barton JC Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B-chronic lymphocytic leukemia | 0 | 0 |
| 1737 | 0 | 0 | 1568 2003 NOV [15] AMERICAN JOURNAL OF HUMAN GENETICS 73(5):197-197 Kohlhase J; Schubert L; Liebers M; Hennekam RCM; Rauch A; Becker K; Mohammed SN; Wright M; Hannibal MC; Newbury-Ecob R; Reardon W SALL4 mutations result in a range of clinically overlapping phenotypes, including Okihiro syndrome, Holt-Oram syndrome, Acro-Reno-Ocular syndrome and patients previously reported to represent Thalidomide Embryopathy. | 0 | 0 |
| 1738 | 0 | 0 | 1569 2003 NOV [15] AMERICAN JOURNAL OF HUMAN GENETICS 73(5):286-286 Pan P; Omlin K; Rosenthal J; Padilla O; Stadecker M; Demmer L A case of Restrictive Dermopathy with survival beyond the neonatal period and novel experience with thalidomide therapy | 0 | 0 |
| 1739 | 0 | 0 | 1599 2003 NOV [15] BIOFUTUR (238):42-43 Knoll M The return of thalidomide | 0 | 0 |
| 1740 | 9 | 20 | 1684 2003 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 123(3):436-441 Thomas DA; Estey E; Giles FJ; Faderl S; Cortes J; Keating M; O'Brien S; Albitar M; Kantarjian H Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia | 1 | 2 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1741 | 1 | 1 | 1685 2003 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 123(3):563-563 Younis T; Alam A; Paplham P; Spangenthal E; McCarthy P Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma (vol 121, pg 191, 2003) | 0 | 1 |
| 1742 | 1 | 3 | 1686 2003 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 123(4):747-748 Mileshkin L; Prince HM; Seymour JF; Biagi JJ Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide | 0 | 0 |
| 1743 | 0 | 3 | 1687 2003 NOV [15] BRITISH JOURNAL OF HAEMATOLOGY 123(4):748-748 Luminari S; Federico M; Baldini L Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide - Response to Mileshkin et al. | 0 | 0 |
| 1744 | 0 | 0 | 1691 2003 NOV [15] CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION 12(11):1288S-1288S Hsu C; Chen HN; Chen LT; Wu CY; Hsieh FJ; Cheng AL Use of power Doppler sonography and circulating angiogenic factors to assess the potential antiangiogenic effect of thalidomide in hepatocellular carcinoma. | 0 | 0 |
| 1745 | 4 | 39 | 1694 2003 NOV [15] CELLULAR AND MOLECULAR BIOLOGY 49(7):1117-1124 Ezell TN; Maloney N; Githua JW; Taylor LD Exposure to the anti-TNF-alpha drug thalidomide induces apoptotic cell death in human T leukemic cells | 0 | 0 |
| 1746 | 19 | 46 | 1752 2003 NOV [15] JOURNAL OF INVESTIGATIVE DERMATOLOGY 121(5):1060-1065 Deng L; Ding WH; Granstein RD Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells | 1 | 1 |
| 1747 | 2 | 5 | 1758 2003 NOV [15] JOURNAL OF PEDIATRICS 143(5):692-694 Yasui K; Misawa Y; Shimizu T; Komiyama A; Kawakami T; Mizoguchi M Thalidomide therapy for juvenile-onset entero-Behcet disease | 0 | 1 |
| 1748 | 0 | 0 | 1766 2003 NOV [15] JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
| 1749 | 3 | 6 | 1785 2003 NOV [15] LEUKEMIA 17(11):2237-2238 Mehta P; Hussein M Thalidomide as anti-inflammatory therapy for multiple myeloma | 0 | 0 |
| 1750 | 2 | 6 | 1786 2003 NOV [15] LEUKEMIA 17(11):2238-2238 Rajkumar SV; Witzig TE Thalidomide as anti-inflammatory therapy for multiple myeloma - Reply | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1751 | 0 | 0 | 1605 2003 NOV 16 BLOOD 102(11):33A-33A Mesa RA; Elliott MA; Faoro L; Tefferi A Durable and unmaintained remissions with thalidomide-based drug therapy in myelofibrosis with myeloid metaplasia: Long term outcome analysis of 2 prospective trials. | 0 | 0 |
| 1752 | 0 | 0 | 1606 2003 NOV 16 BLOOD 102(11):56B-56B Ballester G; Ballester O; Daitch L; Kutlar A Response to thalidomide therapy in multicentric Castleman's disease. | 0 | 0 |
| 1753 | 0 | 0 | 1607 2003 NOV 16 BLOOD 102(11):148A-148A Palumbo A; Bertola A; Musto P; Nunzi M; De Stefano V; Callea V; Rotoli B; Petti MC; Caravita T; Lauta VM; Patti C; Bringhen S; Cavallo F; Falco P; Carella AM; Liberati AM; Boccadoro M Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma. | 0 | 1 |
| 1754 | 0 | 0 | 1608 2003 NOV 16 BLOOD 102(11):148A-149A Dimopoulos MA; Anagnostopoulos A; Hamilos G; Zomas A; Efstathiou E; Grigoraki V; Poziopoulos C; Gika D; Xilouri I; Zorzou MP; Anagnostopoulos N Pulsed cyclophosphamide, thalidomide and dexamethasone: Long term follow-up of an oral regimen for previously treated patients with multiple myeloma. | 0 | 0 |
| 1755 | 0 | 0 | 1609 2003 NOV 16 BLOOD 102(11):149B-149B Moutouh-de Parseval LA; Glezer E; Corral L; Muller G; Brady H; Mercurio F; Chan K Immunomodulatory thalidomide analogs modulate hematopoietic stem cells developmental pathway. | 0 | 0 |
| 1756 | 0 | 0 | 1610 2003 NOV 16 BLOOD 102(11):236A-236A Zangari M; Barlogie B; Jacobson J; Rasmussen E; Burns M; Kordsmeier B; Shaughnessy JD; Anaissie EJ; Thertulien R; Fassas A; Lee CK; Schenkein D; Zeldis JB; Tricot G VTD regimen comprising velcade (V) plus thalidomide (T) and added DEX (D) for non-responders to V+T effects a 57% PR rate among 56 patients with myeloma (M) relapsing after autologous transplant. | 0 | 4 |
| 1757 | 0 | 0 | 1611 2003 NOV 16 BLOOD 102(11):237A-237A Niesvizky R; Pekle K; Lyons L; Pearse RN; Bergsagel PL; Schuster MW; Cho HJ; Leonard JP; Coleman M Dexamethsone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin(TM)) on response rate. interim results of a prospective, sequential, randomized trial. | 0 | 0 |
| 1758 | 0 | 0 | 1612 2003 NOV 16 BLOOD 102(11):237A-237A Agrawal NR; Hussein MA; Elson P; Karam MA; Reed J; Srkalovic G Pegylated Doxorubicin(D), Vineristine(V), reduced frequency Dexamethasone(D) and Thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients. | 0 | 0 |
| 1759 | 0 | 0 | 1613 2003 NOV 16 BLOOD 102(11):259B-259B Cooper BW; Koc ON; Lazarus HM; Laughlin MJ; Myerson HJ; Creger RJ Phase II study of fludarabine, carboplatin, topotecan, and thalidomide for patients with acute myelogenous leukemia and advanced myelodysplastic syndromes. | 0 | 0 |
| 1760 | 0 | 0 | 1614 2003 NOV 16 BLOOD 102(11):327B-328B Musto P; Falcone A; Sanpaolo G; Bodenizza C; La Sala A; Carella AM Once-weekly recombinant erythropoietin plus thalidomide for the anemia of low-to-intermediate risk myelodysplastic syndromes. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1761 | 0 | 0 | 1615 2003 NOV 16 BLOOD 102(11):330B-330B Leb LV; Becker P; Brettler D; Church AA; Khanani SA; Rooney JJ; Seidler CW; Yang J; Woda B The potentiating effect of low dose thalidomide given in combination with epoetin alfa in patients with myelodysplastic syndrome (MDS) having low International Prognostic Scoring Systems (IPSS). | 0 | 0 |
| 1762 | 0 | 0 | 1616 2003 NOV 16 BLOOD 102(11):353B-353B Chanan-Khan AA; Stein L; David S; Takeshita K; Platt J; Miller K; Fallon A; Czuczman MS; Hawthorn L Thalidomide (T) induced in vivo changes in gene expression profile (GEP) of malignant chronic lymphocytic leukemia (CLL) cells. | 0 | 0 |
| 1763 | 0 | 0 | 1617 2003 NOV 16 BLOOD 102(11):359B-359B Kay N; Geyer S; Yaqoob I; Phyliky R; Kutteh L; Li CY Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): A North Central Cancer Treatment Group (NCCTG) study. | 0 | 0 |
| 1764 | 0 | 0 | 1618 2003 NOV 16 BLOOD 102(11):366B-367B Okikawa Y; Sakai A; Kuroda Y; Katayama Y; Takimoto Y; Okita H; Kimura A Analysis of the maturity of myeloma cells (plasma cells) is useful to select effective chemotherapy including thalidomide and to predict the progressive disease. | 0 | 0 |
| 1765 | 0 | 0 | 1619 2003 NOV 16 BLOOD 102(11):378B-378B Agrawal NR; Srkalovic G; Sup S; Hsi ED; Elson P; Hussein MA Impact of pegylated doxorubicin(D), vincristine(V), reduced frequency dexamethasone(D) and thalidomide(T) {DVd-T} on bone marrow microvessel density (MVD) in newly diagnosed multiple myeloma (MM) patients (pts). | 0 | 0 |
| 1766 | 0 | 0 | 1620 2003 NOV 16 BLOOD 102(11):380B-380B Myers B; Russell NH; McMillan AK Use of a novel combination chemotherapy for AL-amyloidosis: Cyclophosphamide, thalidomide and dexamethasone - Serum free light chain (SFLC) and serum amyloid protein P (SAP) scan results. | 0 | 0 |
| 1767 | 0 | 0 | 1621 2003 NOV 16 BLOOD 102(11):381B-381B Breitkreutz I; Cremer FW; Benner A; Moehler T; Fruehauf S; Herrmann D; Ho AD; Goldschmidt H Peripheral blood stem cell collection after CAD plus G-CSF in multiple myeloma: No influence of previous thalidomide administration. | 0 | 0 |
| 1768 | 0 | 0 | 1622 2003 NOV 16 BLOOD 102(11):381B-381B Offidani M; Marconi M; Corvatta L; Malerba L; Olivieri A; Barulli S; Capelli D; Rupoli S; Leoni P Combination therapy with Caelyx, dexamethasone and thalidomide (CDT) for multiple myeloma (MM): Preliminary results of a phase II-III study. | 0 | 0 |
| 1769 | 0 | 0 | 1623 2003 NOV 16 BLOOD 102(11):382B-382B Musto P; Bodenizza C; Falcone A; Sanpaolo G; Cascavilla N; Melillo L; Dell'Olio M; La Sala A; Mantuano S; Nobile M; Scalzulli PR; Greco MM; Carella AM; Beltrami G; Carella AM Treatment of myeloma patients relapsed after frontline autologous stem cell transplantation with the association of thalidomide, dexamethasone and zoledronate. | 0 | 1 |
| 1770 | 0 | 0 | 1624 2003 NOV 16 BLOOD 102(11):382B-382B Novoselac AV; Reddy S; Ohsumi F; Sherman RE; Samaha S Acute myeloid leukemia in patient with multiple myeloma treated with thalidomide. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1771 | 0 | 0 | 1625 2003 NOV 16 BLOOD 102(11):382B-383B Caravita T; Siniscalchi A; Niscola P; Santinelli S; Buccisano F; Montanaro M; De Fabritiis P; Amadori S Low dose thalidomide in combination with dexamethasone and cyclophosphamide for management of relapsed/refractory multiple myeloma. | 0 | 0 |
| 1772 | 0 | 0 | 1626 2003 NOV 16 BLOOD 102(11):383B-383B Guglielmelli T; Capella S; Mattioli G; Guerrasio A; Saglio G Thalidomide at very low dosage may represent an effective therapy in relapsed and refractory multiple myeloma. | 0 | 0 |
| 1773 | 0 | 0 | 1627 2003 NOV 16 BLOOD 102(11):383B-384B Spencer A; Roberts A; Bailey M; Schran H; Lynch K No evidence for an adverse interaction between zoledronic acid and thalidomide: Preliminary safety analysis from the Australasian Leukaemia and Lymphoma Group (ALLG) MM6 myeloma trial. | 0 | 0 |
| 1774 | 0 | 0 | 1628 2003 NOV 16 BLOOD 102(11):385B-385B Di Raimondo F; Pennisi A; Buglio D; Fiumara P; Palumbo GA; Giustolisi R Addition of low dose Cyclophosphamide to the combination of Thalidomide and Dexamethasone in patients with relapsed/refractory multiple myeloma. | 0 | 0 |
| 1775 | 0 | 0 | 1629 2003 NOV 16 BLOOD 102(11):385B-386B Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M Combined thalidomide-dexametasone and zoledronic acid induce a reduction of bone resorption markers in newly diagnosed multiple myeloma patients. | 0 | 0 |
| 1776 | 0 | 0 | 1630 2003 NOV 16 BLOOD 102(11):386B-386B Kyriakou CA; D'Sa SP; Flory A; Hanslip J; Peggs KS; Yong KL Cyclophosphamide, dexamethasone and thalidomide (CDT) is a well tolerated and effective regimen in advanced relapsed/refractory myeloma. | 0 | 0 |
| 1777 | 0 | 0 | 1631 2003 NOV 16 BLOOD 102(11):387B-387B Kumar S; Witzig TE; Wellik L; Fonseca R; Dispenzieri A; Lacy MQ; Lust JA; Kyle RA; Gertz MA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma. | 0 | 0 |
| 1778 | 0 | 0 | 1632 2003 NOV 16 BLOOD 102(11):389B-389B Chanan-Khan AA; Miller K; Srinivasan S; David S; McCarthy P; Alam A; Bernstein ZP; Czuczman MS Velcade (Vel), Doxil (R) (Dox) and low-dose thalidomide (Thal) as salvage therapy for patients (pts) with relapsed/refractory multiple myeloma (MM). | 0 | 0 |
| 1779 | 0 | 0 | 1633 2003 NOV 16 BLOOD 102(11):390B-390B Oyan B; Koc Y; Kars A; Turker A; Tekuzman G; Kansu E Achieving high remission rate with use of autologous HSCT, thalidomide maintenance and non-myeloablative allogeneic HSCT in patients with multiple myeloma. | 0 | 0 |
| 1780 | 0 | 0 | 1634 2003 NOV 16 BLOOD 102(11):443A-443A El-Sherbiny YM; Davies FE; Cook G; Johnson RJ; Cullen MJ; Sah A; Rawstron AC; Richards SJ; Morgan GJ NK cell repertoire in myeloma and the impact of thalidomide. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1781 | 0 | 0 | 1635 2003 NOV 16 BLOOD 102(11):448A-448A Cavo M; Zamagni E; Tosi P; Cellini C; de Vivo A; Cangini D; Tonelli M; Testoni N; Grafone T; Tacchetti P; Soverini S; Terragna C; Tura S; Baccarani M Primary therapy with thalidomide and dexamethasone in preparation to autologous transplantation for multiple myeloma. | 0 | 0 |
| 1782 | 0 | 0 | 1636 2003 NOV 16 BLOOD 102(11):449A-449A Patten PE; Ahsan G; Kazmi M; Fields PA; Chick GW; Jones RR; Bradwell AR; Schey SA The early use of the serum free light chain assay in patients with relapsed refractory myeloma receiving treatment with a thalidomide analogue (CC-4047). | 0 | 0 |
| 1783 | 0 | 0 | 1637 2003 NOV 16 BLOOD 102(11):450A-450A Zervas K; Dimopoulos MA; Hatziharisi E; Anagnostopoulos A; Papaioannou M; Mitsouli C; Panagiotidis P; Korantzis L; Tzilianos M; Maniatis A Primary treatment of mutiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. | 0 | 0 |
| 1784 | 0 | 0 | 1638 2003 NOV 16 BLOOD 102(11):450A-451A Comenzo RL; Hassoun H; Reich L; Klimek V; Kewalramani T; Dhodapkar M; Drake L; Hedvat C; Teruya-Feldstein J; Fleisher M; Filippa DA; Nimer SD Doxorubicin and dexamethasone (AD) followed by thalidomide and dexamethasone (TD) as initial therapy for symptomatic patients with multiple myeloma. | 0 | 0 |
| 1785 | 0 | 0 | 1639 2003 NOV 16 BLOOD 102(11):453A-453A Lacy MQ; Dispenzieri A; Gertz MA; Wilzig TE; Greipp PR; Fonseca R; Lust JA; Kumar S; Zeldenrust S; Kyle RA; Snow D; Hayman SR; Sidor CF; Treston AM; Zeldis JB; Rajkumar SV ENMD-0995 (S 3-APG), a novel thalidomide analogue, has promising clinical activity for patients with relapsed refractory multiple myeloma. Preliminary results of a phase I clinical trial. | 0 | 1 |
| 1786 | 0 | 0 | 1640 2003 NOV 16 BLOOD 102(11):453A-454A Abonour R; Ganjoo K; Fausel C; Yiannoutsos C; Juliar BE; Wood LL; Smith GG; Walker P; Cripe LD A phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma, a Hoosier Oncology Group (HOG) trial: HEM01-21. | 0 | 0 |
| 1787 | 0 | 0 | 1641 2003 NOV 16 BLOOD 102(11):454A-454A Anagnostopoulos A; Efstathiou E; Hamilos G; Zorzou MP; Kastritis E; Dimopoulos MA Patterns of progression in myeloma patients treated with thalidomide-based regimens: High incidence of extramedullary progression without serologic relapse. | 0 | 0 |
| 1788 | 0 | 0 | 1642 2003 NOV 16 BLOOD 102(11):454A-454A Anaissie EJ; Jacobson J; Fassas AB; Zangari M; Thertulien R; VanRhee F; Talamo G; Tricot G; Wendling C; Davis CK; Hollmig K; Barlogie B Safety of total therapy II with or without thalidomide (THAL) for newly diagnosed myeloma: A study of 475 consecutive patients. | 0 | 0 |
| 1789 | 0 | 0 | 1643 2003 NOV 16 BLOOD 102(11):456B-456B Yakoub-agha I; Mohty M; Attal M; Marit G; Bulabois CE; Sotto JJ; Gratecos N; Rio B; Vernant JP; Dib M; Garban F; Cahn JY; Jouet JP; Facon T Thalidomide (THAL) as salvage therapy for relapsed multiple myeloma (MM) after allogeneic stem cell transplantation (SCT). | 0 | 0 |
| 1790 | 0 | 0 | 1644 2003 NOV 16 BLOOD 102(11):489B-490B Grosskreutz CL; Egan R; Scigliano E; Fruchtman SM; Isola LM Thalidomide maintenance after autologous stem cell transplantation for multiple myeloma. | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1791 | 0 | 0 | 1645 2003 NOV 16 BLOOD 102(11):490B-490B Castro J; Davila J; Perez S; Flores L; Lopez A; Roman A; Pacheco E; Fernandex A; Fradera J; Garcia R; Merle S; Velez-Garcia E High dose chemotherapy (HDC) with autologous transplant (AT) followed by thalidomide (T) as maintenance in patients (P) with multiple myeloma (MM). | 0 | 0 |
| 1792 | 0 | 0 | 1646 2003 NOV 16 BLOOD 102(11):554A-554A Biemond BJ; Havik SR; Meijers JCM; Levi MM; Van Oers MHJ Strong thrombogenic activity of the combined administration of thalidomide and doxorubicin in experimental thrombosis in the rabbit. | 0 | 0 |
| 1793 | 0 | 0 | 1647 2003 NOV 16 BLOOD 102(11):675A-675A Chanan-Khan AA; Fallon A; Miller K; Bernstein ZP; Hernandez F; Alam A; McCarthy P; Mohr A; Czuczman MS Thalidomide (T) and fludarabine (F) as front-line therapy for patients (pts) with previously untreated chronic lymphocytic leukemia (CLL): Results of a phase I trial. | 0 | 0 |
| 1794 | 0 | 0 | 1648 2003 NOV 16 BLOOD 102(11):684A-684A Badros AZ; Ratterree B; Natt S; Rapoport AP; Zeldis JB; Frankel SR; Meisenberg B; Takebe N; Zwiebel JA; Zhang B; Fenton R Phase I/II trial of oblimersen sodium (G3139), dexamethasone (Dex) and thalidomide (Thal) in patients with relapsed multiple myeloma. | 0 | 1 |
| 1795 | 0 | 0 | 1649 2003 NOV 16 BLOOD 102(11):686A-686A Hovenga S; Daenen SMGJ; de Wolf JTM; van Imhoff GW; Kluin-Nelemans HC; Vellenga E Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma. A prospective phase III study. | 0 | 0 |
| 1796 | 0 | 0 | 1650 2003 NOV 16 BLOOD 102(11):687A-687A Latif T; Elson P; Karam MA; Reed J; Tahir K; Srkalovic G; Hussein MA Incidence of renal impairment (RI) in multiple myeloma (MM) patients receiving combination chemotherapy and thalidomide (Thal) with bisphosphonate therapy. | 0 | 0 |
| 1797 | 0 | 0 | 1651 2003 NOV 16 BLOOD 102(11):687A-687A Zangari M; Barlogie B; Lee CK; Kang SH; Fassas A; Thertulien R; Van Rhee F; Talamo G; Burns M; Anaissie EJ; Tricot G; Jacobson J Increment in bone phophatase (ALP) in myeloma patients during treatment with velcade, thalidomide and dexamethasome (VTD) is a strong predictor for response. | 0 | 0 |
| 1798 | 0 | 0 | 1652 2003 NOV 16 BLOOD 102(11):689A-689A Hattori Y; Kakimoto T; Okamoto S; Iguchi T; Morita K; Tanigawara Y; Ikeda Y Plasma concentration of thalidomide and clinical efficacy in patients with multiple myeloma. | 0 | 0 |
| 1799 | 0 | 0 | 1653 2003 NOV 16 BLOOD 102(11):691A-691A Feyler S; Jackson G; Rawstron A; El-Sherbiny YM; Snowden JA; Johnson RJ Thalidomide maintenance following high dose therapy in multiple myeloma: A UK myeloma forum phase 2 study. | 0 | 1 |
| 1800 | 0 | 0 | 1654 2003 NOV 16 BLOOD 102(11):691A-692A Hoyer B; Fenk R; Steidl U; Kondakci M; Germing U; Haas R; Kobbe G Single agent thalidomide for treatment of first relapse following high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. | 0 | 0 |